Treatment-resistant depression (TRD) affects approximately 30% of major depressive disorder(MDD) cases and represents a major unmet clinical need. Ketamine produces rapid antidepressanteffects in TRD, but response is variable and no validated biomarker predicts who will respond.Multiple independent studies have now shown that baseline EEG features -- particularly vigilancestage distribution and...
BMC PsychiatryApril 26, 2026Sergi López-rodríguez, Cinto Segalàs, Eva Real et al.
BACKGROUND: Patients with obsessive–compulsive disorder (OCD) and comorbid major depressive disorder (MDD) represent a severe subgroup with increased treatment resistance, greater functional impairment, and limited therapeutic options. Intranasal esketamine is a rapidly acting treatment for resistant depression, with emerging interest in potential anti-obsessional effects. However, prospective...
Scientific ReportsApril 25, 2026Audrey G. Evers, Elizabeth C. Stade, Aadesh Salecha et al.1 citation
Enthusiastic media coverage of psychedelics as a treatment for mental health disorders is perceived as hyped compared to coverage of established treatments. To measure potential hype, we conducted pre-registered analyses comparing media coverage (e.g., newspaper articles) of psychedelics to FDA-approved antidepressants for major depressive disorder and posttraumatic stress disorder. We used...
Over the past 25 years, the use of 5-MeO-DMT in informal and underground settings has contributed a substantial, yet underrecognized, body of knowledge relating to the efficacy of 5-MeO-DMT in alleviating depressive symptoms. Traditional models of drug development, typically characterized by structured trials and regulatory milestones, rarely consider findings from these alternative routes. The...
Interleukin-6 (IL-6) has been implicated as a potential predictor of ketamine response in treatment-resistant depression (TRD). Esketamine, the S-enantiomer of ketamine, produces rapid antidepressant effects and offers improved safety and intranasal administration. To examine whether baseline IL-6 predicts treatment response to esketamine in individuals with TRD. Fourteen adults with TRD...
Background/Objectives: Major depressive disorder (MDD) remains a leading cause of disability worldwide and exhibits substantial biological heterogeneity that is not adequately captured by current symptom-based diagnostic systems. While the classical monoamine hypothesis has historically guided antidepressant development, it does not fully account for variability in treatment response, delayed...
Objective: To estimate the prevalence of various parasomnias in the general Norwegian adult population and explore their associations with insomnia, anxiety, and depression. Methods: A cross-sectional online survey was conducted in September 2024 among 1002 adults (50.7% male, mean age 50.3), drawn from a large population-based sample from a national web panel. Participants reported lifetime...
Background The mediating role of mindfulness among lesbian, gay, bisexual, transgender and queer (LGBTQ) university students from lower-middle-income countries like the Philippines remains unreported. Aims To examine the mediating role of mindfulness in the associations of depression, anxiety, stress and mental well-being among LGBTQ university students. Methods This cross-sectional...
Journal of Psychoactive DrugsApril 23, 2026Brayan Jonas Mano-Sousa, Maria Clara Gama Fontes, Ana Clara Anacleto Gonçalves et al.
Suicide, particularly in treatment-resistant depression (TRD), remains a pressing global health issue, with over 700,000 annual deaths. Existing treatments often have limited efficacy and delayed onset, creating a need for rapid-acting interventions. Ayahuasca, a traditional Amazonian psychedelic, has shown potential for rapidly reducing suicidal ideation. Our systematic review evaluated the...
Objectives: To test the effectiveness of mindful compassion integrated with body-mind-spirit (BMS) therapy delivered through a blended face-to-face and online approach for breast cancer patients. Methods: This randomized controlled trial (RCT) assigned 39 breast cancer patients to either a blended group (partial face-to-face and online sessions) or an online-only group. Both received eight...